Fourth International Symposium on Hereditary Breast and Ovarian Cancer (BRCA 2012)
Venue: Mont-Royal Centre
|Event Date/Time: Apr 25, 2012||End Date/Time: Apr 27, 2012|
|Registration Date: Apr 20, 2012|
|Early Registration Date: Jan 25, 2012|
|Abstract Submission Date: Jan 25, 2012|
Hosted by the Hereditary Breast and Ovarian Cancer Foundation and the Program in Cancer Genetics at McGill University, the Symposium will again offer an exciting and innovative program for clinical researchers, genetic counselors, and primary care providers.
Some of the finest researchers and world-renowned experts from Canada, the USA, Australia, and Europe will present stimulating lectures to inform, educate and motivate Symposium attendees. The confirmed Faculty of over 30 speakers includes, among others, Jan Klijn, MD, PhD, Erasmus University Hospital, Rotterdam, The Netherlands; Andrea Richardson, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, USA; Jorge Reis-Filho, MD, PhD, Breakthrough Breast Cancer Research Center, Institute of Cancer Research, London, UK; Doug Easton, PhD, Cambridge University, Cambridge, UK; Charlotte Kuperwasser, PhD, Tufts University, Boston, MA, USA; Karen Gelmon, MD, BC Cancer Agency, Vancouver, BC, Canada; Steven Narod, MD, University of Toronto, Toronto, ON, Canada; and David Bowtell, PhD, Peter MacCallum Cancer Centre, Melbourne, Australia.
Topics will include:
BRCA1/2 mutations, variants and databases
Molecular pathology of hereditary breast and ovarian cancer
Whatâ€™s new in BRCA-related ovarian cancer molecular genetics?
Biology and basic research
Management and emerging clinical issues
Issues for BRCA carriers choosing preventive surgery
Models of service delivery: does the standard model fit?
Non-BRCA1/2 genetic factors associated with cancer risk
Genome-wide approaches to breast cancer risk
Special Interest Group Discussions
Round Table Case Discussions
And to close the Symposium, we are honoured to have Dr. Alan Ashworth, CEO of The Institute of Cancer Research, London, UK, to give the Marla Miller Memorial Lecture which is entitled Synthetic Lethality: a new paradigm for treating cancer in susceptible individuals.
The tradition of a full day conference for patients, families and interested members of the public will also continue as part of our commitment to educate and inform the wider population about BRCA 1 and 2.
The deadline for submitting abstracts for oral presentation is November 18, 2011. Abstracts on all topics related to hereditary breast and ovarian cancer are welcome. A full list of subject categories as well as submission instructions can be found on the Symposium website. Poster abstracts may be submitted until January 25, 2012